Muller & Phipps (India)BOM:501477 54 Days Payable is 126.31 as of Mar. 2026, which is 74% below its 10-year median of 493.11. GuruFocus rates BOM:501477 with a GF Score™ of 54/100 and a GF Value™ of ₹281.24 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 606 Healthcare Providers & Services companies, Muller & Phipps (India) ranks better than 77.23% on this metric.
The historical rank and industry rank for Muller & Phipps (India)'s Days Payable or its related term are showing as below:
BOM:501477'
s Days Payable Range Over the Past 10 Years
Min: 84.25 Med: 493.11 Max: 668.06
Current: 133.85
During the past 13 years, Muller & Phipps (India)'s highest Days Payable was 668.06. The lowest was 84.25. And the median was 493.11.
BOM:501477's Days Payable is ranked better than 77.23% of 606
companies
in the Healthcare Providers & Services industry
Industry Median: 57.32
vs BOM:501477: 133.85
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Muller & Phipps (India) Days Payable Competitor Comparison
For the Pharmaceutical Retailers subindustry, Muller & Phipps (India)'s Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Muller & Phipps (India) Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Muller & Phipps (India)'s Days Payable distribution charts can be found below:
* The bar in red indicates where Muller & Phipps (India)'s Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Muller & Phipps (India)'s Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Muller & Phipps (India) (BOM:501477) has a Days Payable of 126.31 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Muller & Phipps (India) and its competitors. This is 74% below median its historical median of 493.11. Over the past decade, Muller & Phipps (India)'s Days Payable has ranged from 84.25 to 668.06. According to the industry distribution chart, Muller & Phipps (India) ranks #138 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 22.8%.
Is Muller & Phipps (India)'s Days Payable too high?
Muller & Phipps (India)'s current Days Payable of 126.31 is 74% below median its 10-year median of 493.11. Over the past 10 years, this metric has ranged from a low of 84.25 to a high of 668.06. The Healthcare Providers & Services industry median Days Payable is 57.32. Muller & Phipps (India)'s value of 126.31 is 120.4% above this industry median. Based on the distribution chart, Muller & Phipps (India) ranks #138 out of 606 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Muller & Phipps (India) has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Muller & Phipps (India)'s Days Payable compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Muller & Phipps (India) ranks #138 out of 606 companies for Days Payable. This places Muller & Phipps (India) in the top 23% of its industry — outperforming the majority of peers. The industry median Days Payable is 57.32. Muller & Phipps (India)'s value of 126.31 is 120.4% above this benchmark. Historically, Muller & Phipps (India)'s own Days Payable has ranged from 84.25 to 668.06 over the past decade. While the company's 10-year median is 493.11 vs. the industry median of 57.32, Muller & Phipps (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 57.32, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Muller & Phipps (India)'s current Days Payable of 126.31 is 120.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Muller & Phipps (India) and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 57.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Muller & Phipps (India)'s current Days Payable is 126.31, which is 74% below median its own 10-year median of 493.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Muller & Phipps (India) stock overvalued right now?
Based on GuruFocus' analysis, Muller & Phipps (India) (BOM:501477) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹281.24, compared to a current price of ₹219.95 — trading 21.8% below its estimated fair value. The current Days Payable is 126.31, which is 74% below median its 10-year median of 493.11 and 120.4% above the Healthcare Providers & Services industry median of 57.32. Muller & Phipps (India)'s overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Muller & Phipps (India) (BOM:501477), the current Days Payable is 126.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Muller & Phipps (India) (BOM:501477) Overvalued in 2026?
Based on GuruFocus' analysis, Muller & Phipps (India) stock appears to be undervalued.
The current stock price of ₹219.95 is trading 21.8% below its estimated GF Value™ of ₹281.24.
GuruFocus considers Muller & Phipps (India) to be Modestly Undervalued.
Key valuation signals for BOM:501477:
Days Payable: 126.31 (74% below median its 10-year median of 493.11)
GF Value™: ₹281.24 vs. price of ₹219.95 (21.8% below fair value)
Industry Position: 120.4% above the Healthcare Providers & Services median (#138 of 606)
No single metric tells the full story. See the BOM:501477 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Muller & Phipps (India) Ltd is engaged in the marketing of over-the-counter medical preparations and home care products. The operating segments of the company are Cosmetic/toiletry, Medicated preparation, Food Products, and Others, of which a majority of the revenue is derived from the Medical preparation segment. The company's product portfolio includes medicated dental products, ayurvedic skin ointment, and home care products. Its brand names include Cavisan, Cavidine, and Nixoderm.
54GF Score
Get the complete analysis for BOM:501477
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:501477 has been successfully added to your 
